By Tim Nedoba
October 2019 – If you’re like me, you’ve seen advertisements from law firms seeking class-action lawsuits against Gilead, the maker of Truvada. Truvada is the primary drug in the PrEP program. The PrEP program is designed to help reduce the spread of HIV.
GoGuide Magazine reached out to one to one the law firms promoting the class-action suits, Jackson and Tucker, based in Atlanta for a statement regarding the Facebook ads. As of press time, GoGuide had yet received a call back from the firm.
PrEP (pre-exposure prophylaxis)
is a prescription medicine that can help reduce the risk of contracting
HIV-1 through sex when taken every day and used together with safer sex practices.
GoGuide reached out to the HIV Clinic at the University of Iowa Hospitals and Clinics about Truvada and was emailed the following statement from Jack Stapleton, M.D,
“The older form of Truvada (TDF) is associated with reduced bone density and kidney problems in a small percentage of people. It is a very well tolerated drug clinically which is why it became one of the leading drugs used to treat HIV over the past 20 years,”
Jack Stapleton, M.D. is a Professor, Division of Infectious Diseases; Depts. of Internal Medicine & Microbiology and Immunology; Director, Levitt Center for Viral Pathogenesis.
Iowa Department of Public Health (IDPH) was also contacted for this article, and they “…believe strongly in these programs as safe and effective ways to fight the spread of HIV in Iowa” IDPH administers the CDC grant.